Expertise in
2
conditions

Dr. Paul G. Montgomery

Hematology Oncology | Oncology | Hematology
St Lukes Clinic-Treasure Valley LLC
100 E Bannock St, 
Boise, ID 
Expertise in
2
conditions
St Lukes Clinic-Treasure Valley LLC
100 E Bannock St, 
Boise, ID 

Overview

Paul Montgomery is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boise, Idaho.

Dr. Montgomery is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Diffuse Large B-Cell Lymphoma (DLBCL), and Ovarian Cancer.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology Oncology
Oncology
Hematology

Licenses

Internal Medicine in ID

Hospital Affiliations

St Luke's Regional Medical Center
St Luke's Wood River Medical Center
St Lukes Magic Valley Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO

Locations

ST LUKES CLINIC-TREASURE VALLEY LLC
100 E Bannock St, Boise, ID 83712
Other Locations
ST LUKES CLINIC-TREASURE VALLEY LLC
608 W Hays St, Boise, ID 83702
ST LUKES CLINIC-TREASURE VALLEY LLC
725 Pole Line Rd W, Twin Falls, ID 83301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: November 20, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

12 Total Publications

Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.
Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.
Journal: Dermatology and therapy
Published: April 02, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Peyman Haghighat
Hematology | Oncology
Expertise in
15
conditions
Dr. Peyman Haghighat
Hematology | Oncology

St. Luke's Meridian Medical Center

520 S Eagle Rd, 
Meridian, ID 
 (7.9 miles away)
208-706-5651
Languages Spoken:
English
See accepted insurances

Peyman Haghighat is a Hematologist and an Oncologist practicing medicine in Meridian, Idaho. Dr. Haghighat is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Lung Cancer.

Expertise in
9
conditions
Dr. Stephanie Hodson
Hematology | Oncology
Expertise in
9
conditions
Dr. Stephanie Hodson
Hematology | Oncology

Saint Alphonsus Regional Medical Center

1055 N Curtis Rd, 
Boise, ID 
 (3.1 miles away)
208-367-3131
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephanie Hodson is a Hematologist and an Oncologist practicing medicine in Boise, Idaho. Dr. Hodson is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Prostate Cancer, and Familial Prostate Cancer.

Expertise in
15
conditions
Dr. Gerardo Perez
Oncology
Expertise in
15
conditions
Dr. Gerardo Perez
Oncology

St. Luke's Regional Medical Center

190 E Bannock St, 
Boise, ID 
 (0.1 miles away)
208-381-4171
Languages Spoken:
English
See accepted insurances

Gerardo Perez is an Oncologist practicing medicine in Boise, Idaho. Dr. Perez is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Oophorectomy.

Frequently Asked Questions about Dr. Paul G. Montgomery

How do I make an appointment with Dr. Paul G. Montgomery?

You can book an appointment with Dr. Paul G. Montgomery by calling their office at 208-381-2983. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul G. Montgomery a top-rated expert for Ovarian Carcinosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul G. Montgomery is classified as an Advanced expert for Ovarian Carcinosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul G. Montgomery specialize in?

While Dr. Paul G. Montgomery is a Hematology Oncology, they have specific expertise in Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Paul G. Montgomery participate in research or clinical trials?

Yes. Dr. Paul G. Montgomery has published 12 articles and abstracts on conditions like Ovarian Carcinosarcoma. You can view a list of Dr. Paul G. Montgomery's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul G. Montgomery accept my insurance?

Dr. Paul G. Montgomery accepts most major insurance plans, including CareFirst. We recommend calling the office directly at 208-381-2983 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Montgomery's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile